Preclinical Efficacy of the Novel Competitive NAMPT Inhibitor STF-118804 in Pancreatic Cancer

Oncotarget - United States
doi 10.18632/oncotarget.18841
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Therapeutic Efficacy of a Novel βIII/βIV-tubulin Inhibitor (VERU-111) in Pancreatic Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination With Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer

Cancer Research
Cancer ResearchOncology
2019English

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Curaxin CBL0137 Eradicates Drug Resistant Cancer Stem Cells and Potentiates Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Oncotarget
Oncology
2014English

WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2017English

Preclinical Evaluation of a Novel Triple-Acting PIM/PI3K/mTOR Inhibitor, IBL-302, in Breast Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2020English

64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Novel Lignan and Stilbenoid Mixture Shows Anticarcinogenic Efficacy in Preclinical PC-3M-luc2 Prostate Cancer Model

PLoS ONE
Multidisciplinary
2014English

GEMMs as Preclinical Models for Testing Pancreatic Cancer Therapies

DMM Disease Models and Mechanisms
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy